COVID-19 Therapeutics Information Page

Notice

• As of 6/25/2021, the United States Department of Health and Human Services (HHS) has suspended nationwide distribution of bamlanivimab + etesivimab due to combined frequencies of SARS-CoV-2 P.1/Gamma and B.1.351/Beta variants throughout the US now exceeding 11% and trending upward. As a result, Healthcare Providers are encouraged to use the alternative authorized monoclonal antibody therapy REGEN-COV2. Based on this new policy change from the federal government, MDHHS recommends suspending the use of bam/ete and immediately transitioning to REGEN-COV. Additional information regarding this announcement can be found here.